paclitaxel

Drug-Coated Balloons (DCB): Sirolimus vs. Paclitaxel in De Novo Lesions in Small Vessels

The use of drug-coated balloons (DCB) offers the advantage of avoiding permanent stent implants, thus reducing the incidence of in-stent restenosis (ISR), neoatherosclerosis, and late in-stent thrombosis. Additionally, the use of DCB reduces the duration of dual antiplatelet therapy. Current evidence supports the use of DCB for ISR treatment (Class I) compared with drug-eluting stents<a href="https://solaci.org/en/2023/11/28/drug-coated-balloons-dcb-sirolimus-vs-paclitaxel-in-de-novo-lesions-in-small-vessels/" title="Read more" >...</a>

TCT 2023 | ALIGN AR trial

TCT 2023 | In Stent Restenosis: Sirolimus vs. Paclitaxel Coated Balloons

This was a prospective, multicenter, randomized study including 130 patients with instent restenosis treated with sirolimus coated balloons (DCB S) and 128 treated with paclitaxel coated balloons (DCB P).&nbsp; Primary end point was late lumen loss (LLL) at 12 months.&nbsp; There were no significant differences between the groups. Mean patient age was 63, 75% were<a href="https://solaci.org/en/2023/10/30/tct-2023-in-stent-restenosis-sirolimus-vs-paclitaxel-coated-balloons/" title="Read more" >...</a>

Resultados del estudio COMPARE a 2 años: Balones cubiertos de Paclitaxel con bajas dosis vs altas dosis

Results of the COMPARE Study After 2 Years: Low Dose vs. High Dose Paclitaxel-Coated Balloons

The development of new devices and techniques has expanded the range of patients who benefit from endovascular treatment of femoropopliteal lesions. Paclitaxel-eluting devices have improved clinical results and treated-vessel patency at follow-up compared with conventional angioplasty. Currently, devices with different doses of paclitaxel are available in the market. The COMPARE (Compare I Pilot Study for<a href="https://solaci.org/en/2022/10/14/results-of-the-compare-study-after-2-years-low-dose-vs-high-dose-paclitaxel-coated-balloons/" title="Read more" >...</a>

SAFE-PAD: Dispositivos liberadores de paclitaxel en enfermedad periférica

ACC 2021 | SAFE-PAD: Paclitaxel-Eluting Devices in Peripheral Disease

This work was conducted alongside the US Food and Drug Administration (FDA) to investigate the association between all-cause mortality and paclitaxel-eluting devices in peripheral vascular disease. According to data from SAFE-PAD, presented at the American College of Cardiology (ACC) 2021 Congress and simultaneously published in JAMA, there is no increase in mortality compared with conventional<a href="https://solaci.org/en/2021/05/19/acc-2021-safe-pad-paclitaxel-eluting-devices-in-peripheral-disease/" title="Read more" >...</a>

balon liberador de paclitaxel eficacia a largo plazo

Felling Reassured with Paclitaxel Coated Devices in Peripheral Artery Disease

This big analysis shows rapid absorption of paclitaxel coated devices for PCI in femoropopliteal territory, which reassures us about its alleged association to increased mortality. In fact, survival, amputation-free survival and cardiovascular events rate resulted better with paclitaxel coated devices in the treatment of chronic limb ischemia.&nbsp; This study emphasizes the difference that might exist<a href="https://solaci.org/en/2020/02/04/felling-reassured-with-paclitaxel-coated-devices-in-peripheral-artery-disease/" title="Read more" >...</a>

Seguridad de los balones con paclitaxel en enfermedad vascular periférica

Safety of Paclitaxel-Coated Balloons in Peripheral Vascular Disease

Everybody keeps wondering whether drug-coated balloons can actually increase mortality. If that is the case, there is an even harder question in need of an answer: what would be the physiopathology for such increase in mortality? As a lukewarm message, the US Food and Drug Administration recommended a special informed consent form when these devices<a href="https://solaci.org/en/2019/10/22/safety-of-paclitaxel-coated-balloons-in-peripheral-vascular-disease/" title="Read more" >...</a>

Efecto a largo plazo de los balones liberadores con bajas dosis de paclitaxel

New FDA Updates on Paclitaxel Device Outcomes

A new FDA letter confirms late mortality signal with paclitaxel eluting stents and paclitaxel coated balloons in peripheral territory. Even though this recently published letter confirms data, there are no new recommendations on the use of these devices. After careful consideration of their own analyzis outcomes and a 2-day discussion of an advisory panel especially<a href="https://solaci.org/en/2019/08/12/new-fda-updates-on-paclitaxel-device-outcomes/" title="Read more" >...</a>

TAVI en insuficiencia aórtica pura, nuevos dispositivos con nuevos resultados

The FDA Affirms Mortality Signs with Paclitaxel Based Devices

Evidently, we are still uncertain. The information goes both ways, even on our own web page, we have been coming and going just like any other publication around the world. After a 2-day debate, the Circulatory System Devices FDA panel has confirmed the tendency to higher mortality with paclitaxel-based devices and is expected to debate<a href="https://solaci.org/en/2019/06/19/the-fda-affirms-mortality-signs-with-paclitaxel-based-devices/" title="Read more" >...</a>

Efecto a largo plazo de los balones liberadores con bajas dosis de paclitaxel

Mortality and Paclitaxel Devices, Data Are Aligning

5 years ago, several prospective randomized studies confirmed paclitaxel coated balloons were safe and effective in femoropopliteal territory. However, a recently published meta-analysis of heterogeneous studies including both paclitaxel coated balloons and drug eluting stents has linked these devices to mortality. In addition, higher doses were associated to higher mortality, both at 2 and 5<a href="https://solaci.org/en/2019/06/05/mortality-and-paclitaxel-devices-data-are-aligning/" title="Read more" >...</a>

ivascular

EuroPCR 2019 | EFFPAC: New Peripheral Paclitaxel Coated Balloons, Efficacy with no Sign of Mortality

Paclitaxel coated balloons in peripheral territory have been under the spotlight for alleged increased mortality, which even though not observed in this study, experts insist, calls for new studies with enough statistical power. Compared against plain balloon angioplasty, paclitaxel coated balloons resulted in improved patency and less revascularization at 24 months in superficial or popliteal<a href="https://solaci.org/en/2019/05/29/europcr-2019-effpac-new-peripheral-paclitaxel-coated-balloons-efficacy-with-no-sign-of-mortality/" title="Read more" >...</a>

Top